Search - tctmd.com

Displaying 1 - 4 of 4

Sort: Relevancy | Date

Cardiovascular Safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

Presentation ESC 2021

Cardiovascular Safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

Presenter: Renato D. Lopes

August 31, 2021

PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer

News Conference News ESC 2021

PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer

Michael O'Riordan

August 30, 2021

New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT

News Conference News ESC 2021

New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT

August 28, 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

August 19, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.